Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Aptorum Group Limited
  6. News
  7. Summary
    APM   KYG6096M1069

APTORUM GROUP LIMITED

(APM)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
1.270 USD   +4.10%
05/17Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022
BU
05/02Aptorum Says Rare Cancer Drug Well Tolerated in Early-Stage Study
MT
05/02Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Posting Gains This Afternoon

01/20/2022 | 01:13pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
APTORUM GROUP LIMITED 4.10% 1.27 Delayed Quote.-15.33%
NASDAQ COMP. 3.33% 12131.13 Real-time Quote.-22.46%
NOVOCURE LIMITED 4.73% 83.98 Delayed Quote.11.85%
STAR EQUITY HOLDINGS, INC. 5.14% 0.9895 Delayed Quote.-61.20%
All news about APTORUM GROUP LIMITED
05/17Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, M..
BU
05/02Aptorum Says Rare Cancer Drug Well Tolerated in Early-Stage Study
MT
05/02Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targ..
BU
05/02Aptorum Group Limited Updates on Data from Completed Phase 1 Clinical Trial of SACT-1, ..
CI
04/29APTORUM : Reports 2021 Fiscal Year End Financial Results and Provides Business Update - Fo..
PU
04/29Aptorum Group Limited Reports Earnings Results for the Full Year Ended December 31, 202..
CI
04/29Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Busin..
BU
04/29APTORUM GROUP LIMITED : SEC Filing 6K-4
CO
04/29APTORUM GROUP LIMITED : Annual results
CO
04/29APTORUM GROUP LIMITED : SEC Filing 20 F
CO
More news
Financials (USD)
Sales 2022 1,50 M - -
Net income 2022 -35,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,27x
Yield 2022 -
Capitalization 45,3 M 45,3 M -
Capi. / Sales 2022 30,2x
Capi. / Sales 2023 23,9x
Nbr of Employees 26
Free-Float 25,4%
Chart APTORUM GROUP LIMITED
Duration : Period :
Aptorum Group Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends APTORUM GROUP LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 1,27 $
Average target price 15,00 $
Spread / Average Target 1 081%
EPS Revisions
Managers and Directors
Ian Huen Director
Darren Lui President & Executive Director
Sabrina Khan Chief Financial Officer
Clark Cheng Executive Director & Chief Medical Officer
Wai-Yip Lee Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
APTORUM GROUP LIMITED-15.33%45
NOVO NORDISK A/S-3.80%1 677 391
JOHNSON & JOHNSON5.86%476 521
PFIZER, INC.-8.70%302 483
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098